Condition: Neovascular Age-related Macular Degeneration · Sponsor: Shanghai Refreshgene Technology Co., Ltd.
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
This description comes directly from the study's public registry record.
Xiaorong Li, Master · 8602223346434 · xiaorong.li@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Eye Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06141460